Peerless Peptides

Semaglutide

31-amino-acid acylated GLP-1 receptor agonist with γGlu-AEEA-AEEA-C18 lipidation arm

Semaglutide is a synthetic 31-amino-acid GLP-1 receptor agonist engineered by Lotte Bjerre Knudsen and the Jesper Lau team at Novo Nordisk in Bagsværd. The molecule carries α-aminoisobutyric acid (Aib) at position 8 to block DPP-IV cleavage, an Arg substitution at position 34 to direct regioselective acylation, and a four-block γ-L-Glu, AEEA, AEEA, C18 octadecanedioic-diacid lipidation arm at Lys-26 that binds albumin's FA-7 pocket for an approximately 7-day plasma residence.

Available for laboratory research use only.

2-Day Fast Shipping

>99% Purity

Ships from Florida

USA Made & Tested

Vial size

Choose your supply

Quantity

Independent Lab Results

The most comprehensive testing panel in research peptide commerce. Every batch is independently verified by ILS Laboratories — an ISO/IEC 17025 and PJLA-accredited facility in San Diego, CA.

  • Identity
  • Purity (HPLC)
  • Endotoxin (USP <85>)
  • Sterility (USP <71>)
  • Heavy metals (ICP-MS per USP <233>)
View Certificate of Analysis Program

Biochemical Profile

CAS Number
910463-68-2
Molecular Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol (average); 4111.12 Da (monoisotopic)
Purity
≥98% (HPLC-UV (220 nm and 280 nm) with orthogonal LC-MS deconvolution)
PubChem CID
56843331
Amino Acid Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γE-AEEA-AEEA-C18diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Receptor Targets and Signaling Pathway Context

Semaglutide is a long-acting peptide agonist of the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. The molecule was engineered from native human GLP-1(7-37) by Lotte Bjerre Knudsen and co-workers at Novo Nordisk through three structural changes: an α-aminoisobutyric acid (Aib) at position 8 to block dipeptidyl peptidase-IV (DPP-IV) cleavage at the His-7 / Ala-8 backbone position, an Arg substitution at position 34 to block off-target acylation, and a γ-L-Glu, AEEA, AEEA, C18 octadecanedioic-diacid ("γGlu-2xOEG-C18") lipidation arm attached at the ε-amine of Lys-26. The lipidation arm tethers the peptide non-covalently to plasma albumin at the FA-7 fatty-acid pocket, extending residence time from the approximately 1.5-minute half-life of native GLP-1 to roughly 7 days subcutaneously[1].

GLP-1R activation has been characterized in published pharmacology across four organ systems. In pancreatic β-cells, GLP-1R couples to Gαs and stimulates adenylyl cyclase, raising cytosolic cAMP and activating both protein kinase A (PKA) and the Epac2 exchange factor; glucose-dependent insulin granule exocytosis was first reported in Drucker et al. 1987[2] and the Epac2 mechanism in Holz et al. 1993[3]. In pancreatic α-cells, GLP-1R activation has been associated with paracrine glucagon suppression mediated by δ-cell somatostatin release[1]. In vagal afferent and area-postrema neurons, GLP-1R activation has been associated with delayed gastric emptying and central nausea signaling, with tachyphylaxis over weeks of repeated administration[4].

The central-nervous-system component of GLP-1R pharmacology was genetically dissected by Sisley et al. 2014, who reported that tissue-specific neuronal GLP-1R knockout in mice dissociated the food-intake response from the glucose-homeostasis response, locating the food-intake effect in hypothalamic arcuate proopiomelanocortin (POMC) neurons and nucleus-tractus-solitarius (NTS) preproglucagon (PPG) neurons[5]. The cryo-EM structure of the activated GLP-1R in complex with peptide agonist and Gs heterotrimer was published in Zhang et al. 2017 *Nature*[6], establishing the structural basis of class B GPCR activation for the receptor family.

Semaglutide's lipidation chemistry distinguishes it from earlier GLP-1R agonists. The 2×AEEA mini-PEG spacers extend the C18 distal carboxylate approximately 16 Å from the peptide backbone, enabling a second albumin-contact point at the FA-7 pocket that confers an approximately 100-fold affinity gain over the C16 mono-acid lipidation architecture of the earlier-generation liraglutide molecule[1]. This is the structural change associated with the shift from daily to weekly subcutaneous administration in the clinical-trial program.

Receptor pharmacology specifically at the glucagon and GIP receptors is neutral: semaglutide does not have meaningful agonist activity at either receptor, distinguishing it pharmacologically from the dual GLP-1/GIP agonist tirzepatide and the GLP-1/GIP/glucagon triagonist retatrutide. Comparative head-to-head pharmacokinetic and pharmacodynamic data across the three molecules have been published in industry-sponsored clinical-trial reports.

Research Applications

Discovery Chemistry and Lipidation Engineering Research

Semaglutide is the second-generation product of the lipidated-GLP-1 engineering program at Novo Nordisk, building on the earlier liraglutide molecule reported in Knudsen et al. 2000[7]. The semaglutide *J Med Chem* discovery paper (Lau et al. 2015) reported the structure-activity rationale for the three core changes: Aib-8 for DPP-IV resistance, Arg-34 for regioselective acylation chemistry, and the γGlu-2xOEG-C18 lipidation arm at Lys-26[1].

The synthesis chemistry is dominated by two technical features. Aib-8 coupling is sterically hindered and is published as requiring HATU activation with double couplings of 60-120 minutes and acetic-anhydride capping, with similar coupling kinetics described for the Aib-1 position in the related growth-hormone-releasing peptide ipamorelin. The Lys-26 acylation requires orthogonal protection chemistry (Fmoc-Lys(ivDde) or Fmoc-Lys(Mtt) at position 26 versus Fmoc-Lys(Boc) elsewhere), hydrazine-driven Dde removal post-assembly, and sequential coupling of the γGlu, AEEA, AEEA, and C18 mono-tBu blocks before global TFA cleavage.

Lotte Bjerre Knudsen received the Lasker-DeBakey Clinical Medical Research Award in 2024 and was inducted into the National Inventors Hall of Fame in 2023, recognizing the engineering arc from native GLP-1 to semaglutide.

GLP-1 Receptor Pharmacology Research

Semaglutide has been characterized in receptor-binding, signal-transduction, and downstream-signaling assays for activity at the GLP-1R. Native GLP-1(7-37) biology was characterized across 1983-1987 by Joel Habener at Massachusetts General Hospital (proglucagon cloning, *Nature* 1983), Svetlana Mojsov at Rockefeller University (identification of GLP-1(7-37) as the active form, 1986-1987), and Daniel Drucker at the University of Toronto (glucose-dependent insulinotropic action, *PNAS* 1987)[2].

Holz et al. 1993 established the Epac2 exchange-factor pathway as a parallel cAMP effector alongside PKA in β-cell insulin granule release[3]. Cryo-electron microscopy of the activated GLP-1R in complex with peptide agonist and Gs heterotrimer was reported by Zhang et al. 2017[6], establishing the structural basis for class B GPCR activation in the broader receptor family. The genetic dissection of central GLP-1R contributions to food intake versus glucose homeostasis was reported by Sisley et al. 2014 using tissue-specific GLP-1R knockout in mice[5].

The receptor pharmacology of semaglutide is among the most rigorously characterized in the broader peptide-pharmacology literature, with cryo-EM structural data, genetic-knockout validation, and an approximately 40-year accumulated experimental record across academic and industry laboratories.

Long-Acting Incretin Pharmacokinetics Research

Semaglutide's approximately 7-day subcutaneous plasma residence has been investigated as a model for the broader class of lipidated peptide therapeutics. The pharmacokinetic mechanism is non-covalent binding of the C18 octadecanedioic-diacid distal carboxylate to the FA-7 fatty-acid pocket of plasma albumin, mediated by the 2×AEEA mini-PEG spacers that provide approximately 16 Å of geometric reach[1].

A distinct oral-bioavailability technology paired with semaglutide tablet formulations uses the salcaprozate sodium (SNAC) absorption enhancer, with the transcellular gastric-absorption mechanism characterized by Buckley et al. 2018 in *Science Translational Medicine*[8]. The SNAC formulation provides oral bioavailability of approximately 0.4-1.0 percent of the equivalent subcutaneous dose, requiring approximately 100-fold higher delivered dose to achieve comparable systemic exposure.

The lipidation architecture has been benchmarked against the earlier-generation C16 mono-acid liraglutide molecule[7] and against alternative albumin-tethering strategies including the Fc-fusion approach used in the GLP-1 agonist dulaglutide and the antibody-conjugate approach used in the longer-cycle bispecific maridebart cafraglutide. Across these architectures, the lipidated 2×AEEA-C18-diacid is associated with the longest subcutaneous half-life reported for a non-Fc-tethered GLP-1R agonist in the published literature.

Comparative Multi-Receptor Incretin Analog Research

Semaglutide is the most extensively characterized member of the GLP-1 mono-agonist class and is the published reference point for comparative pharmacology against later-generation multi-receptor agonists. The dual GLP-1/GIP agonist tirzepatide (LY3298176) was characterized by Coskun et al. 2018 in *Molecular Metabolism*[9] with a 39-amino-acid GIP-backbone scaffold; tirzepatide and semaglutide have been compared in head-to-head clinical trials sponsored by the originating manufacturers[10]. The GLP-1/GIP/glucagon triagonist retatrutide (LY3437943) was characterized by Coskun et al. 2022 in *Cell Metabolism* and reported in a Phase 2 trial by Jastreboff et al. 2023 in the *New England Journal of Medicine*.

The amylin analog cagrilintide has been investigated alongside semaglutide in the REDEFINE Phase 3 program sponsored by Novo Nordisk; the co-administration formulation is referred to in the published research as CagriSema. Combined administration has been examined in industry-sponsored clinical-trial protocols; the existing literature on combined safety and efficacy in humans is limited to those sponsor-led studies, and broader combined-receptor pharmacology has not been independently established outside the originating sponsor's research program.

The Amgen bispecific maridebart cafraglutide ("Maritide") pairs a GIP-receptor antagonist with a GLP-1 receptor agonist on a monthly-dosing antibody scaffold, representing a pharmacologically opposite GIP-arm strategy to tirzepatide. Comparative head-to-head data across these architectures remain limited as of May 2026.

Lipidation-Arm Integrity and QC Research

Semaglutide's plasma residence depends entirely on the integrity of the four-block γGlu-AEEA-AEEA-C18 lipidation arm at Lys-26. Hydrolysis of any of the four amide bonds in the arm yields a peptide that retains intact backbone immunoreactivity and intact GLP-1R binding in vitro but loses the approximately 7-day half-life. The published failure modes include loss of the terminal C18 diacid (mass shift -298 Da), des-AEEA(1) (-145 Da), des-AEEA(2) (-290 Da), des-γGlu (-129 Da), and full-arm hydrolysis (-1085 Da). A vendor batch can read 99 percent pure by HPLC-UV at 220 nm against a single C18 column and still be 30-60 percent des-lipidated, because the naked peptide can co-elute with the intact molecule on a single isocratic column.

The diagnostic test that resolves this failure mode is LC-MS deconvolution distinguishing the intact 4113.58 Da molecule from each des-arm variant, paired with orthogonal-column retention-time confirmation on HILIC or C4 phases. Additional QC tests in the published quality framework include chiral verification by Marfey's reagent (Aib-2 and D-amino-acid impurities), a Trp-25 oxidation panel (+16 Da), an Asn deamidation panel (+1 Da), Karl Fischer water content (acetate hydrates declare), residual-solvent panel, ICH Q3D heavy-metals limits, endotoxin (LAL), bioburden, and counter-ion identity (acetate versus TFA).

Novo Nordisk and Eli Lilly have published peer-reviewed analytical surveys of compounded and gray-market GLP-1 product samples reporting off-target peptide impurities, D-amino-acid racemization, incomplete or modified lipidation arms, endotoxin failures, and identity discrepancies on mass spectrometry. Conflict-of-interest disclosures are noted; the underlying findings have been corroborated by independent academic chemistry analyses and by FDA enforcement actions.

Clinical Status and FDA-Approved-Drug-Substance Context

Semaglutide is an FDA-approved drug substance and is the most extensively characterized peptide in the broader research literature, with the published PubMed corpus reaching approximately 6,000-7,500 records as of May 2026 across approximately 40,000 randomized participants in the named Phase 3 program (SUSTAIN in type 2 diabetes; PIONEER in oral type 2 diabetes; STEP in chronic-weight research; SELECT in cardiovascular outcomes; FLOW in chronic kidney disease; ESSENCE in MASH).

Selected published Phase 3 primary-endpoint outcomes include the STEP-1 trial (NCT03548935, n=1,961) reported in Wilding et al. 2021 with a primary-endpoint difference of -14.9 percent versus -2.4 percent placebo at week 68[11]; the SELECT trial (NCT03574597, n=17,604) reported in Lincoff et al. 2023 with a major-adverse-cardiac-events hazard ratio of 0.80 in non-diabetic obese adults with established cardiovascular disease[12]; and the SUSTAIN-6 cardiovascular trial in type 2 diabetes reported in Marso et al. 2016[13]. The EVOKE and EVOKE+ Phase 3 trials in Alzheimer's disease (NCT04777396, NCT04777409, combined n=3,808) missed their pre-specified primary endpoint at week 104 in March 2026 and the one-year extension was discontinued[14].

The FDA officially resolved the semaglutide drug shortage on February 21, 2025; enforcement discretion for 503A outsourcing facilities ended April 22, 2025 and for 503B outsourcing facilities on May 22, 2025. The OFA versus FDA preliminary-injunction motion was denied April 24, 2025. Semaglutide is FDA-approved as a finished drug product; it is not lawfully compoundable as a bulk substance under 503A or 503B as of May 2026. FDA issued approximately 50 warning letters on September 9, 2025 and approximately 30 additional warning letters on March 3, 2026 to outsourcing facilities and telehealth distributors. The federal criminal floor was set by *United States v. Watkins* (D. Utah, 1:26-cr-00015-DBB, April 1, 2026), the first indictment of a US-licensed physician for selling misbranded peptides, with semaglutide named in the indictment. The Lanham Act civil floor was set by *Eli Lilly & Co. v. Mochi Health LLC* (N.D. Cal., Judge Corley), whose amended complaint survived a motion to dismiss in April 2026 on a manufacturer customer-diversion and reputational-injury theory.

Reconstitution & Storage

Recommended Diluent
Bacteriostatic water (0.9% benzyl alcohol) or sterile saline
Storage (lyophilized)
-20°C, dry, dark, inert headspace, >24 months
Storage (reconstituted)
2-8°C, single-use aliquots preferred; lipidation-arm hydrolysis clock begins at reconstitution
Shelf Life
>24 months lyophilized at -20°C

Research References

  1. [1] Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726PMID:26308095
  2. [2] Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84(10):3434-3438. PMID:3033647
  3. [3] Holz GG, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993;361(6410):362-365. PMID:8381211
  4. [4] Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565. PMID:21430088
  5. [5] Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest. 2014;124(6):2456-2463. PMID:24762441
  6. [6] Zhang Y, Sun B, Feng D, et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature. 2017;546(7657):248-253. PMID:28492259
  7. [7] Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664-1669. PMID:10780916
  8. [8] Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. PMID:30429357
  9. [9] Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID:30473097
  10. [10] Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID:34170647
  11. [11] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. STEP-1 trial NCT03548935 (n=1,961); week-68 primary endpoint reported as -14.9% vs -2.4% placebo body-weight change; cited here for primary-endpoint reporting in chronic-weight Phase 3 research. PMID:33567185
  12. [12] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. SELECT trial NCT03574597 (n=17,604); MACE HR 0.80 (95% CI 0.72-0.90). PMID:37952131
  13. [13] Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. SUSTAIN-6 trial. PMID:27633186
  14. [14] Novo Nordisk EVOKE and EVOKE+ Phase 3 program in Alzheimer's disease (NCT04777396, NCT04777409); combined n=3,808; pre-specified primary endpoint not met at week 104. Sponsor topline disclosure March 2026; one-year extension discontinued. Peer-reviewed publication pending as of May 2026.
  15. [15] Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795-1797. PMID:37796527
  16. [16] Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384-390. PMID:36356111
  17. [17] Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. PMID:38958939
  18. [18] USA v. Justin Bradley Watkins, D. Utah, 1:26-cr-00015-DBB, indictment filed April 1, 2026. First federal indictment of a US-licensed physician for selling misbranded peptides; semaglutide named in indictment. Eli Lilly & Co. v. Mochi Health LLC, N.D. Cal. (Judge Corley); amended complaint surviving motion to dismiss April 2026 on manufacturer Lanham Act standing.

Scientific Journal Author

Lotte Bjerre Knudsen, MSc, DSc

Novo Nordisk A/S, Måløv/Bagsværd, Denmark (Chief Scientific Advisor for Research and Early Development, Globe Institute, University of Copenhagen)

Landmark Publications

  • Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664-1669. (PMID 10780916; liraglutide discovery)
  • Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. (PMID 26308095; semaglutide discovery, with Knudsen as senior corresponding author)
  • Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. (PMID 31031702; engineering retrospective)

Lotte Bjerre Knudsen and the Jesper Lau team are independently cited here as the originating discovery and engineering research group for semaglutide at Novo Nordisk. Knudsen received the 2024 Lasker-DeBakey Clinical Medical Research Award and was inducted into the National Inventors Hall of Fame in 2023. There is no affiliation or commercial relationship between Knudsen, the Lau team, Novo Nordisk, the Globe Institute at the University of Copenhagen, and Peerless Peptides.

Frequently Asked Questions